Apoptosis News and Research RSS Feed - Apoptosis News and Research

Apoptosis is programmed cell death, the body's normal method of disposing of damaged, unwanted, or unneeded cells.
Review sheds light on current therapeutic targets of miRNA-associated chemoresistance in EOC

Review sheds light on current therapeutic targets of miRNA-associated chemoresistance in EOC

Epithelial ovarian cancer (EOC) is the most lethal disease among gynecologic malignancies. Patients with an advanced disease often relapse due to the development of chemoresistance. Chemotherapy failure is a consequence of acquired drug resistance which may potentially be due to multiple mechanisms including miRNA-mediated gene regulation. [More]
TSRI scientists develop novel technique for finding drug candidates

TSRI scientists develop novel technique for finding drug candidates

Scientists at The Scripps Research Institute have developed a powerful new method for finding drug candidates that bind to specific proteins. [More]
Already-approved drugs can fight apoptosis evasion in cancer

Already-approved drugs can fight apoptosis evasion in cancer

Cancer cells don't die when they're supposed to. Animal and human bodies follow an orderly process of birthing new cells and killing old ones. But cancer cells escape programmed cell death, called apoptosis, and multiply uncontrollably. [More]
PharmaMar announces initiation of pivotal plitidepsin clinical trial in patients with T-cell lymphomas

PharmaMar announces initiation of pivotal plitidepsin clinical trial in patients with T-cell lymphomas

PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma. [More]
Study underscores importance of developing PRMT5 inhibitors as promising treatment for GB patients

Study underscores importance of developing PRMT5 inhibitors as promising treatment for GB patients

A new study suggests that blocking an enzyme called PRMT5 in tumor cells could be a promising new strategy for the treatment of glioblastoma (GB), the most aggressive and lethal form of brain cancer. [More]
New effort in biomedical engineering may improve heart repair

New effort in biomedical engineering may improve heart repair

Jianyi "Jay" Zhang, M.D., Ph.D., brought his biomedical engineering expertise to the University of Alabama at Birmingham to fix hearts. [More]
Drug candidate delivered by plant-virus-based carrier shows promise for triple-negative breast cancer

Drug candidate delivered by plant-virus-based carrier shows promise for triple-negative breast cancer

In a pair of firsts, researchers at Case Western Reserve University and Massachusetts Institute of Technology have shown that the drug candidate phenanthriplatin can be more effective than an approved drug in vivo, and that a plant-virus-based carrier successfully delivers a drug in vivo. [More]
Researchers explore use of miR-192 as clinical marker for pancreatic cancer

Researchers explore use of miR-192 as clinical marker for pancreatic cancer

Pancreatic cancer is regarded as the cancer type with the lowest survival rates. Fewer than seven in 100 patients survive the first five years after diagnosis. Clinicians attribute this devastating prognosis to two circumstances: Pancreatic cancers often do not cause any signs or symptoms and by the time they are detected they have already reached a very advanced stage in most cases. [More]
Researchers design ProAgio protein that may potentially treat cancer, other illnesses

Researchers design ProAgio protein that may potentially treat cancer, other illnesses

A protein designed by researchers at Georgia State University can effectively target a cell surface receptor linked to a number of diseases, showing potential as a therapeutic treatment for an array of illnesses, including cancer, according to the research team. [More]
Novel way of directly activating Bak protein can trigger cell death

Novel way of directly activating Bak protein can trigger cell death

Melbourne researchers have discovered a new way of triggering cell death, in a finding that could lead to drugs to treat cancer and autoimmune disease. [More]
Cornell researchers develop nanoparticle-based drug delivery mechanism for combination cancer therapy

Cornell researchers develop nanoparticle-based drug delivery mechanism for combination cancer therapy

A team of researchers from Cornell University in Ithaca, New York demonstrated a drug delivery mechanism that utilizes two independent vehicles, allowing for delivery of chemically and physically dis-tinct agents. [More]
Researchers identify potential ways in which cancer cells may develop resistance to BET inhibitors

Researchers identify potential ways in which cancer cells may develop resistance to BET inhibitors

A team of Walter and Eliza Hall Institute researchers has worked out how a new class of anti-cancer drugs kills cancer cells, a finding that helps explain how cancer cells may become resistant to treatment. [More]
Phase I study of triple drug combination shows promise in multiple myeloma patients

Phase I study of triple drug combination shows promise in multiple myeloma patients

PharmaMar announces the positive results from a Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma. [More]
TAK1 deficit protects mice from obesity

TAK1 deficit protects mice from obesity

Obesity and subsequent complications are increasing in frequency worldwide. The accumulation of adipose tissue is associated with increased inflammation, and it has been proposed that modification of proinflammatory responses could alter adipose tissue composition. [More]
Phase 2 results of AbbVie’s venetoclax in patients with R/R CLL with 17p deletion published in The Lancet Oncology

Phase 2 results of AbbVie’s venetoclax in patients with R/R CLL with 17p deletion published in The Lancet Oncology

AbbVie, a global biopharmaceutical company, today announced The Lancet Oncology published results from the Phase 2, single arm, open label trial studying venetoclax in patients with relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL) with 17p deletion. [More]
Unlocking the dark proteome: an interview with Dr Kriwacki

Unlocking the dark proteome: an interview with Dr Kriwacki

The term dark proteome refers to proteins whose structural features and thus functions are not well understood. Many proteins within the dark proteome do not fold into stable three-dimensional structures. These proteins are called intrinsically disordered proteins (IDPs) and feature highly flexible, disordered confirmations. [More]
Scientists clarify molecular mechanism of Visomitin drug

Scientists clarify molecular mechanism of Visomitin drug

An international team of scientists led by researchers from the Lomonosov Moscow State University succeeded to clarify the molecular mechanism of a drug created in Russia and designed to prevent the damaging of cell mitochondria by reactive oxygen species. This work is published in the journal Oxidative Medicine and Cellular Longevity. [More]
Scientists visualize apoptosis in live zebrafish using FLIM OPT method

Scientists visualize apoptosis in live zebrafish using FLIM OPT method

A promising approach for watching cell signaling processes in their physiological context: Scientists visualize apoptosis in live zebrafish using fluorescence lifetime imaging with optical projection tomography to map FRET biosensor activity in space and time. [More]
MUSC Hollings Cancer Center receives $8.9 million grant to explore signaling in sphingolipids

MUSC Hollings Cancer Center receives $8.9 million grant to explore signaling in sphingolipids

The Medical University of South Carolina's Hollings Cancer Center received an $8.9 million grant from the National Cancer Institute designed to foster collaboration across clinical and laboratory research for the study of signaling in sphingolipids, a class of lipids known to be involved in the growth of solid tumor cancers. [More]
Study hints at new therapeutic approach to mitigate effects of prenatal Zika virus infection

Study hints at new therapeutic approach to mitigate effects of prenatal Zika virus infection

The U.S. Centers for Disease Control and Prevention recently concluded that Zika virus infection in pregnant women can stunt neonatal brain development, leading to babies born with abnormally small heads, a condition known as microcephaly. Now, for the first time, researchers at University of California San Diego School of Medicine have determined one way Zika infection can damage developing brain cells. [More]
Advertisement
Advertisement